Since both cisplatin and radiation are mainstay treatment modalities in SCCHN, future work will be focused on assessing the ability of CD271 inhibition to enhance chemoradiation sensitivity of these CD44+CD271+ TICs. Here, CD44 is linked to head and neck squamous cell carcinoma.